https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/25 2026-05-23T18:58:42Z 2026-05-23T18:58:42Z Davis, Gina Kinchington, Matthew Brown, Mark https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/704 2026-04-22T04:58:21Z 2024-01-01T00:00:00Z

Title: Does Routine EGFR Reporting Adversely Affect Medication Dosing in the Elderly? Authors: Davis, Gina; Kinchington, Matthew; Brown, Mark Abstract: Aim: To identify if drug dosing errors occur in patients age ≥ 65 based on usual reporting of estimated glomerular filtration rate (eGFR) com pared with reporting by the Cockcroft-Gault (CG) equation. practice Background: Creatinine-based GFR equations are commonly used in clinical to guide drug dosing. The Australian Therapeutic Guidelines recommend use of the CG derived eGFR as the basis for drug dosing guidelines (Therapeutic Guidelines, 2019. Estimating glomerular filtration rate in adults). However, the standard reporting of eGFR within Australian hospitals and laboratories is via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) equation. Methods: We studied a single-centre prospective cohort of aged care patients, age ≥ 65-years-old, admitted under the Geriatrics Team at Port Macquarie Base Hospital, Australia, over 3 months. 163 patients were included, with 8 excluded as weights were not recorded in the year prior. Creatinine was calculated on admission and in the 48 hours prior to discharge and the average of these two results used to calcu late eGFR using CG and CKD-EPI 2021. Results: Of the 208 medications prescribed that required adjustment based on renal function, there were 38 (18%) dosing errors. The most commondrugs in question were perindopril, apixaban and ciprofloxacin. Twenty-nine (76%) of these errors occurred regardless of which eGFR calculation was used. The other nine (24%) dosing errors (7 over-dosed and 2 under-dosed) occurred if using CKD-EPI 2021 rather than CG. Conclusions: Minimal differences occur in drug dosing when using CG and CKD-EPI 2021 formulas. However, when discrepancies occur, use of CKD-EPI 2021 typically results in medication overdoses, which could result in adverse reactions in an at-risk population.

2024-01-01T00:00:00Z Sydenham, A. https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/565 2025-03-04T00:51:49Z 1993-01-01T00:00:00Z

Title: Enhancing renal support therapy in northern NSW Authors: Sydenham, A. Abstract: No abstract available.

1993-01-01T00:00:00Z Conduit, C. Davis, I. D. Goh, J. C. Kichenadasse, G. Gurney, H. Harris, C. A. Pook, D. Krieger, L. Parnis, F. Underhill, C. Adams, D. Roncolato, F. Joshua, A. Ferguson, T. Prithviraj, P. Morris, M. Harrison, M. Begbie, S. Hovey, E. George, M. Liow, E. C. Link, E. K. McJannett, M. Gedye, C. Australian and New Zealans Urogental and Prostrate Cancer Trils Group (ANZUP) UNISoN Investigators https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/464 2025-01-31T03:18:41Z 2024-02-01T00:00:00Z

Title: A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma Authors: Conduit, C.; Davis, I. D.; Goh, J. C.; Kichenadasse, G.; Gurney, H.; Harris, C. A.; Pook, D.; Krieger, L.; Parnis, F.; Underhill, C.; Adams, D.; Roncolato, F.; Joshua, A.; Ferguson, T.; Prithviraj, P.; Morris, M.; Harrison, M.; Begbie, S.; Hovey, E.; George, M.; Liow, E. C.; Link, E. K.; McJannett, M.; Gedye, C.; Australian and New Zealans Urogental and Prostrate Cancer Trils Group (ANZUP); UNISoN Investigators Abstract: Objective: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-cell renal cell carcinoma (nccRCC). Materials and methods: UNISoN (ANZUP1602; NCT03177239) was an open-label, single-arm, phase 2 clinical trial that recruited adults with immunotherapy-naïve, advanced nccRCC. Participants received nivolumab 240 mg i.v. two-weekly for up to 12 months (Part 1), followed by sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab if disease progression occurred during treatment (Part 2). The primary endpoint was objective tumour response rate (OTRR) and secondary endpoints included duration of response (DOR), progression-free (PFS) and overall survival (OS), and toxicity (treatment-related adverse events). Results: A total of 83 participants were eligible for Part 1, including people with papillary (37/83, 45%), chromophobe (15/83, 18%) and other nccRCC subtypes (31/83, 37%); 41 participants enrolled in Part 2. The median (range) follow-up was 22 (16-30) months. In Part 1, the OTRR was 16.9% (95% confidence interval [CI] 9.5-26.7), the median DOR was 20.7 months (95% CI 3.7-not reached) and the median PFS was 4.0 months (95% CI 3.6-7.4). Treatment-related adverse events were reported in 71% of participants; 19% were grade 3 or 4. For participants who enrolled in Part 2, the OTRR was 10%; the median DOR was 13.5 months (95% CI 4.8-19.7) and the median PFS 2.6 months (95% CI 2.2-3.8). Treatment-related adverse events occurred in 80% of these participants; 49% had grade 3, 4 or 5. The median OS was 24 months (95% CI 16-28) from time of enrolment in Part 1. Conclusions: Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.

2024-02-01T00:00:00Z Rawther, T. Rebolledo, B. A. J. Das, K. K. Joshi, N. https://mnclhd.intersearch.com.au/mnclhdjspui/handle/123456789/363 2025-01-07T01:18:39Z 2020-09-01T00:00:00Z

Title: Circumaortic left renal vein: a rare but important anatomical variation to consider prior to a radical nephrectomy Authors: Rawther, T.; Rebolledo, B. A. J.; Das, K. K.; Joshi, N. Abstract: No abstract available.

2020-09-01T00:00:00Z